Halofuginone News and Research

RSS
The hydrobromide salt of halofuginone, a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant Dichroa febrifuga, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters. Collagen type I and MMP-2 play important roles in fibro-proliferative diseases.
New compound may enhance dengue vaccine efficacy by simulating amino acid deficiency

New compound may enhance dengue vaccine efficacy by simulating amino acid deficiency

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

TACT believes that Halo's HT-100 may effectively treat DMD

TACT believes that Halo's HT-100 may effectively treat DMD

Molecular secrets behind halofuginone's power

Molecular secrets behind halofuginone's power

Drug derived from the hydrangea root shows promise for autoimmune disorders

Drug derived from the hydrangea root shows promise for autoimmune disorders

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.